Cohance Lifesciences Q1 FY27 Share Price & Earnings Call Analysis
- Market cap
- ₹18,418 Cr
- P/E
- 171.06
- ROE
- 4.89%
- PEG
- -7.54
- Price to sales
- 8.59
- Debt to equity
- 0.10
- 52W high / low
- ₹786 / ₹280
- Sales growth (5Y)
- 17.57%
- EBITDA margin
- 14.76%
- Net profit margin
- 6.86%
- Promoter holding
- 57.48%
- Sales (last year)
- ₹2,142 Cr
Cohance Lifesciences is a Hyderabad-based CDMO operating across pharmaceutical development, manufacturing, APIs, formulations and specialty chemicals. The company states that it features among the Top 20 CDMOs globally; its Pharma CDMO business works with 19 of the top 20 global innovators, while the API portfolio ranks among the top three suppliers in 8 of its top 10 molecules.[1][2]
Guidance scorecard · Q1 FY27 call
What Cohance Lifesciences Ltd's management guided
and where it ranks in Pharmaceuticals & Biotechnology
Pharmaceuticals & Biotechnology
RevenueQ1 FY27 call
10–20%- H2 FY27 expected to show growth over the previous year with new molecules and reload/older molecules contributing (Umang Vohra).
- Pharma CDMO business projected to have strong sequential Q2FY27 growth compared to Q1FY27, with long-term growth driven by 7 product filings in FY27 (Gunjan Singh, Umang Vohra).
- API+ segment seen as a sustainable, growing business with potential to double over 3-4 years, driven by CNS focus and innovator relationships (Gunjan Singh).
- ADC business currently cost-heavy but expected to improve with pipeline development and revenue growth (Umang Vohra).
2 more points from Cohance Lifesciences Ltd's call on revenue
Create a free account to keep reading this call
MarginsQ1 FY27 call
Up 2%+See what Cohance Lifesciences Ltd said on margins — free account, 30 seconds.
CapexQ1 FY27 call
Planned- Capital expenditure during the quarter was approximately INR 598 million, focused on investing in capabilities required for future growth.
- Investment includes a commercial flow reactor at the Jaggayyapet site, expected to be ready by next quarter.
- Completed debottlenecking initiatives for several products and commissioned a new effluent treatment facility at Ankleshwar to enhance capacity and compliance.
- Ongoing remediation and operational stabilization efforts at the Nacharam facility, supporting CAPA implementation and full normalization.
2 more points from Cohance Lifesciences Ltd's call on capex
Create a free account to keep reading this call
FundraisingQ1 FY27 call
See what Cohance Lifesciences Ltd said on fundraising — free account, 30 seconds.
Order bookQ1 FY27 call
- The company experienced shipment timing and customer approval delays causing Q1FY27 revenue shortfall.
- A commercial restocking order has been secured, with deliveries scheduled across Q2FY27 and Q3FY27.
- The late-stage opportunity funnel has expanded, supporting growth momentum in the second half of FY27.
- The Pharma CDMO segment received meaningful delivery visibility for Q4 FY27 and FY28 due to restocking orders.
- RFQ pipeline is strengthening, backed by numerous Phase 3 KSM commercial supply inquiries from large pharma companies and Western CDMOs.
- Multiple customer programs have progressed through qualification stages, including two Japanese innovators' first qualifications scheduled in FY27.
2 more points from Cohance Lifesciences Ltd's call on the order book
Create a free account to keep reading this call
Ranges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Peers
Pharmaceuticals & Biotechnology companies ranked on guidance
| # | Company | Revenue guided | Margin guided | Market cap | P/E |
|---|---|---|---|---|---|
| 1 | 40%+ | Up 2%+ | ₹556 Cr | 22.1 | |
| 2 | 40%+ | Up 0–2% | ₹215 Cr | 22.2 | |
| 3 | 40%+ | Flat | ₹16,144 Cr | — | |
| 4 | 40%+ | Flat | ₹6,072 Cr | 48.0 | |
| 5 | 40%+ | Flat | ₹40 Cr | — | |
| 6 | 20–40% | Up 2%+ | ₹50,220 Cr | 43.8 |
Sign up free to see every company in the sector ranking and track Cohance Lifesciences Ltd.
Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology rankingFinancials of Cohance Lifesciences Ltd
Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Cohance Lifesciences Ltd
Quarterly Results
Quarter-by-quarter operating performance
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 369.36 | 347.55 | 231.05 | 219.82 | 252.93 | 488.08 | 603.77 | 676.23 | 840.42 | 549.31 | 555.57 | 544.55 | 619.12 |
| Expenses + | 197.50 | 180.59 | 133.09 | 153.74 | 179.58 | 362.98 | 398.40 | 438.86 | 611.20 | 437.30 | 434.62 | 449.20 | 520.44 |
| Operating Profit | 171.86 | 166.96 | 97.96 | 66.08 | 73.35 | 125.10 | 205.37 | 237.37 | 229.22 | 112.01 | 120.95 | 95.35 | 98.68 |
| OPM % | 46.53% | 48.04% | 42.40% | 30.06% | 29.00% | 25.63% | 34.01% | 35.10% | 27.27% | 20.39% | 21.77% | 17.51% | 15.94% |
| Other Income + | 11.40 | 10.67 | 19.84 | 14.34 | 17.05 | 19.41 | 16.19 | 21.56 | -3.73 | 6.07 | 15.60 | 1.30 | -18.35 |
| Interest | 5.03 | 1.15 | 0.50 | 2.16 | 2.30 | 10.20 | 9.61 | 10.80 | 10.45 | 10.18 | 8.76 | 9.11 | 9.19 |
| Depreciation | 12.02 | 12.54 | 11.89 | 12.79 | 17.25 | 31.28 | 37.79 | 43.56 | 54.17 | 45.14 | 44.02 | 46.94 | 51.23 |
| Profit before tax | 166.21 | 163.94 | 105.41 | 65.47 | 70.85 | 103.03 | 174.16 | 204.57 | 160.87 | 62.76 | 83.77 | 40.60 | 19.91 |
| Tax % | 25.41% | 26.44% | 24.51% | 28.59% | 24.67% | 26.85% | 20.62% | 24.97% | 27.18% | 26.07% | 20.75% | 28.52% | 58.26% |
| Net Profit + | 123.97 | 120.59 | 79.56 | 46.75 | 53.37 | 75.37 | 138.24 | 153.48 | 117.15 | 46.40 | 66.39 | 29.02 | 8.31 |
| EPS in Rs | 4.87 | 4.74 | 3.13 | 1.84 | 2.10 | 2.96 | 5.44 | 6.01 | 4.73 | 1.28 | 1.94 | 0.96 | 0.51 |
Financials of Cohance Lifesciences Ltd
Profit & Loss
Annual income statement trend
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales + | 378 | 834 | 1,010 | 1,320 | 1,340 | 1,051 | 1,198 | 2,269 |
| Expenses + | 206 | 449 | 567 | 738 | 766 | 645 | 822 | 1,842 |
| Operating Profit | 172 | 385 | 443 | 582 | 574 | 406 | 375 | 427 |
| OPM % | 45% | 46% | 44% | 44% | 43% | 39% | 31% | 19% |
| Other Income + | 1 | 66 | 68 | 133 | 46 | 62 | 58 | 5 |
| Interest | 3 | 23 | 12 | 9 | 13 | 7 | 12 | 37 |
| Depreciation | 12 | 24 | 32 | 39 | 48 | 55 | 77 | 187 |
| Profit before tax | 158 | 405 | 468 | 668 | 560 | 406 | 344 | 207 |
| Tax % | 31% | 22% | 23% | 32% | 27% | 26% | 23% | 27% |
| Net Profit + | 109 | 317 | 362 | 454 | 411 | 300 | 265 | 150 |
| EPS in Rs | 12.45 | 14.23 | 17.83 | 16.16 | 11.80 | 10.52 | 4.68 | |
| Dividend Payout % | 0% | 20% | 14% | 28% | 37% | 0% | 0% | 0% |
Financials of Cohance Lifesciences Ltd
Balance Sheet
Capital structure and asset base
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.00 | 13 | 25 | 25 | 25 | 25 | 25 | 38 |
| Reserves | 578 | 832 | 1,155 | 1,502 | 1,710 | 2,025 | 1,671 | 3,873 |
| Borrowings + | 83 | 186 | 143 | 97 | 70 | 65 | 279 | 400 |
| Other Liabilities + | 123 | 142 | 151 | 205 | 160 | 138 | 1,056 | 1,418 |
| Total Liabilities | 783 | 1,173 | 1,474 | 1,830 | 1,966 | 2,254 | 3,031 | 5,730 |
| Fixed Assets + | 271 | 357 | 441 | 534 | 663 | 670 | 1,713 | 3,373 |
| CWIP | 111 | 102 | 96 | 30 | 165 | 179 | 256 | 173 |
| Investments | 7 | 338 | 542 | 598 | 536 | 904 | 337 | 529 |
| Other Assets + | 394 | 376 | 395 | 667 | 601 | 501 | 725 | 1,655 |
| Total Assets | 783 | 1,173 | 1,474 | 1,830 | 1,966 | 2,254 | 3,031 | 5,730 |
Financials of Cohance Lifesciences Ltd
Cash Flows
Operating, investing and financing cash movement
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 50 | 407 | 383 | 330 | 457 | 358 | 288 | 368 |
| Cash from Investing Activity + | -65 | -413 | -311 | -136 | -195 | -362 | -253 | -255 |
| Cash from Financing Activity + | 26 | 7 | -76 | -156 | -242 | -14 | 3 | -165 |
| Net Cash Flow | 11 | 1 | -5 | 37 | 20 | -18 | 38 | -51 |
| Free Cash Flow | -6 | 304 | 272 | 255 | 171 | 307 | 132 | 169 |
| CFO/OP | 49% | 128% | 111% | 88% | 105% | 115% | 99% | 102% |
Financials of Cohance Lifesciences Ltd
Ratios
Working capital efficiency and return ratios
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 142 | 51 | 37 | 65 | 30 | 46 | 87 | 110 |
| Inventory Days | 556 | 278 | 243 | 259 | 279 | 268 | 199 | 310 |
| Days Payable | 190 | 113 | 100 | 97 | 63 | 49 | 96 | 157 |
| Cash Conversion Cycle | 509 | 217 | 180 | 228 | 247 | 265 | 190 | 263 |
| Working Capital Days | 205 | 64 | 56 | 108 | 99 | 115 | 74 | 175 |
| ROCE % | 50% | 40% | 41% | 32% | 19% | 15% | 8% |
Guidance history
How Cohance Lifesciences Ltd's guidance has moved, call by call
| Call | Revenue | Margins | Capex | Fundraising | Order book |
|---|---|---|---|---|---|
| Q1 FY27 call → | 10–20% | Up 2%+ | Planned | — | — |
| Q4 FY26 call → | 0–10% | Flat | Planned | — | Rising |
| Q3 FY26 call → | 10–20% | Up 0–2% | Planned | — | Rising |
| Q2 FY26 call → | 20–40% | Flat | Planned | Planned | Rising |
What management guided on each call, newest first. Not investment advice, and not a forecast of returns.
Momentum score · price trend
21 out of 100 — Cooling
Over the past year its share price has done worse than most of the stocks we track.
| Period | Share price change | Better than … of 1,910 stocks |
|---|---|---|
| Last 12 months | −38.8% | 13% |
| Last 6 months | −0.4% | 53% |
| Last 3 months | +13.2% | 82% |
The price is 63.7% below its all-time high of ₹1,327.15 (1 Nov 2024). Stocks more than 20% below their peak have their score halved, so 43 became 21.
How we calculate it
“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,910 Indian companies worth ₹500 Cr or more, with at least a year of prices).
The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For Cohance Lifesciences Ltd: 0.4 × 13 + 0.4 × 53 + 0.2 × 82 = 43, halved to 21 because the price is more than 20% below its all-time high.
Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.
Full methodology →This describes only how the share price has moved up to 29 Oct 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.
Continue your research
What Cohance Lifesciences Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Lincoln Pharmaceuticals Ltd (Q2 FY27)
2,798.12 Lakhs increase (approximately 17.1% growth) . Key results statement takeaways from Lincoln Pharmaceuticals Ltd's Q2 FY27 results statement — and how it
- Alivus Life Sciences Ltd (Q2 FY27)
Q2 FY27 Revenue from Operations: ₹6,820 million, up 16.0% year-on-year (YoY). Key investor presentation takeaways from Alivus Life Sciences Ltd's Q2 FY27 invest
- Strides Pharma Science Ltd (Q2 FY27)
Q2FY27 Revenue: ₹14,297 million, up 17.1% YoY (Page 4, 15) . Key investor presentation takeaways from Strides Pharma Science Ltd's Q2 FY27 investor presentation
- Laurus Labs Ltd (Q2 FY27)
2Q FY27 Revenue:** ₹2,206 crore, up 33% year-on-year (Y-o-Y) and 9% quarter-on-quarter (Q-o-Q). Key investor presentation takeaways from Laurus Labs Ltd's Q2 FY